S&P 500   4,273.68 (+-0.01%)
DOW   33,901.40 (-0.23%)
QQQ   329.93 (+0.44%)
AAPL   174.40 (-0.09%)
MSFT   291.27 (-0.02%)
META   175.30 (+0.26%)
GOOGL   120.55 (+0.84%)
AMZN   142.24 (+0.10%)
TSLA   916.17 (+0.46%)
NVDA   188.11 (+2.60%)
NIO   19.91 (-0.85%)
BABA   90.60 (+0.92%)
AMD   100.66 (+2.43%)
MU   63.02 (+2.27%)
T   18.45 (+0.16%)
CGC   3.82 (-5.91%)
F   16.04 (+0.06%)
GE   79.55 (-0.46%)
DIS   122.76 (-0.04%)
AMC   20.04 (-6.18%)
PYPL   99.01 (-0.41%)
PFE   48.68 (-1.20%)
NFLX   245.38 (+1.75%)
S&P 500   4,273.68 (+-0.01%)
DOW   33,901.40 (-0.23%)
QQQ   329.93 (+0.44%)
AAPL   174.40 (-0.09%)
MSFT   291.27 (-0.02%)
META   175.30 (+0.26%)
GOOGL   120.55 (+0.84%)
AMZN   142.24 (+0.10%)
TSLA   916.17 (+0.46%)
NVDA   188.11 (+2.60%)
NIO   19.91 (-0.85%)
BABA   90.60 (+0.92%)
AMD   100.66 (+2.43%)
MU   63.02 (+2.27%)
T   18.45 (+0.16%)
CGC   3.82 (-5.91%)
F   16.04 (+0.06%)
GE   79.55 (-0.46%)
DIS   122.76 (-0.04%)
AMC   20.04 (-6.18%)
PYPL   99.01 (-0.41%)
PFE   48.68 (-1.20%)
NFLX   245.38 (+1.75%)
S&P 500   4,273.68 (+-0.01%)
DOW   33,901.40 (-0.23%)
QQQ   329.93 (+0.44%)
AAPL   174.40 (-0.09%)
MSFT   291.27 (-0.02%)
META   175.30 (+0.26%)
GOOGL   120.55 (+0.84%)
AMZN   142.24 (+0.10%)
TSLA   916.17 (+0.46%)
NVDA   188.11 (+2.60%)
NIO   19.91 (-0.85%)
BABA   90.60 (+0.92%)
AMD   100.66 (+2.43%)
MU   63.02 (+2.27%)
T   18.45 (+0.16%)
CGC   3.82 (-5.91%)
F   16.04 (+0.06%)
GE   79.55 (-0.46%)
DIS   122.76 (-0.04%)
AMC   20.04 (-6.18%)
PYPL   99.01 (-0.41%)
PFE   48.68 (-1.20%)
NFLX   245.38 (+1.75%)
S&P 500   4,273.68 (+-0.01%)
DOW   33,901.40 (-0.23%)
QQQ   329.93 (+0.44%)
AAPL   174.40 (-0.09%)
MSFT   291.27 (-0.02%)
META   175.30 (+0.26%)
GOOGL   120.55 (+0.84%)
AMZN   142.24 (+0.10%)
TSLA   916.17 (+0.46%)
NVDA   188.11 (+2.60%)
NIO   19.91 (-0.85%)
BABA   90.60 (+0.92%)
AMD   100.66 (+2.43%)
MU   63.02 (+2.27%)
T   18.45 (+0.16%)
CGC   3.82 (-5.91%)
F   16.04 (+0.06%)
GE   79.55 (-0.46%)
DIS   122.76 (-0.04%)
AMC   20.04 (-6.18%)
PYPL   99.01 (-0.41%)
PFE   48.68 (-1.20%)
NFLX   245.38 (+1.75%)
NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$294.33
-4.90 (-1.64%)
(As of 08/18/2022 12:10 PM ET)
Add
Compare
Today's Range
$291.58
$299.74
50-Day Range
$245.39
$305.53
52-Week Range
$176.36
$305.95
Volume
7,767 shs
Average Volume
1.42 million shs
Market Capitalization
$75.48 billion
P/E Ratio
23.79
Dividend Yield
N/A
Price Target
$291.65

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
1.1% Downside
$291.65 Price Target
Short Interest
Healthy
1.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.05mentions of Vertex Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$59.94 M Sold Last Quarter
Proj. Earnings Growth
7.32%
From $12.56 to $13.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

285th out of 1,122 stocks

Pharmaceutical Preparations Industry

132nd out of 551 stocks

VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ:VRTX opened at $299.23 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.50 and a quick ratio of 4.36. Vertex Pharmaceuticals has a 1 year low of $176.36 and a 1 year high of $305.95. The company has a market cap of $76.74 billion, a P/E ratio of 24.19, a PEG ratio of 2.18 and a beta of 0.45. The stock's fifty day moving average price is $281.84 and its 200-day moving average price is $264.59.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 earnings per share for the quarter, beating analysts' consensus estimates of $3.12 by $0.48. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the firm earned $2.80 earnings per share. The firm's revenue for the quarter was up 22.5% compared to the same quarter last year. Sell-side analysts expect that Vertex Pharmaceuticals will post 12.56 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on VRTX shares. Wells Fargo & Company boosted their price target on shares of Vertex Pharmaceuticals from $300.00 to $305.00 in a research report on Friday, May 6th. Robert W. Baird lowered Vertex Pharmaceuticals from an "outperform" rating to a "neutral" rating and set a $250.00 target price for the company. in a research report on Friday, May 6th. Barclays lifted their price target on Vertex Pharmaceuticals from $291.00 to $307.00 and gave the company an "overweight" rating in a research report on Friday, August 5th. Piper Sandler increased their price objective on Vertex Pharmaceuticals from $256.00 to $288.00 and gave the stock a "neutral" rating in a report on Tuesday. Finally, Cowen boosted their target price on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a report on Monday, June 13th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $291.65.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $291.30, for a total transaction of $3,405,005.70. Following the completion of the sale, the chief executive officer now owns 111,153 shares of the company's stock, valued at $32,378,868.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 22,173 shares of the firm's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $303.93, for a total transaction of $6,739,039.89. Following the sale, the chief operating officer now directly owns 45,278 shares of the company's stock, valued at $13,761,342.54. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Reshma Kewalramani sold 11,689 shares of the company's stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $291.30, for a total value of $3,405,005.70. Following the completion of the transaction, the chief executive officer now directly owns 111,153 shares of the company's stock, valued at approximately $32,378,868.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 208,520 shares of company stock valued at $59,937,985. Insiders own 0.40% of the company's stock.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

Vertex Pharmaceuticals (NASDAQ:VRTX) PT Raised to $288.00
3 Stocks to Buy in a New Nasdaq Bull Market
VRTX Stock Provides Multiple Swing Trading Lessons
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
8/04/2022
Today
8/18/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
3,900
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$291.65
High Stock Price Forecast
$365.00
Low Stock Price Forecast
$222.00
Forecasted Upside/Downside
-0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
47.10%

Debt

Sales & Book Value

Annual Sales
$7.57 billion
Cash Flow
$12.27 per share
Book Value
$46.53 per share

Miscellaneous

Free Float
255,433,000
Market Cap
$75.48 billion
Optionable
Optionable
Beta
0.45

Social Links


Key Executives














VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2022?

17 brokers have issued twelve-month price objectives for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $222.00 to $365.00. On average, they anticipate the company's stock price to reach $291.65 in the next twelve months. This suggests that the stock has a possible downside of 2.5%.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2022?

Vertex Pharmaceuticals' stock was trading at $219.60 at the start of the year. Since then, VRTX shares have increased by 36.3% and is now trading at $299.23.
View the best growth stocks for 2022 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its earnings results on Thursday, August, 4th. The pharmaceutical company reported $3.60 EPS for the quarter, topping analysts' consensus estimates of $3.12 by $0.48. The pharmaceutical company had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 31.22% and a net margin of 38.26%. The firm's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 EPS.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, August, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion, compared to the consensus revenue estimate of $8.58 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (6.53%), State Street Corp (4.78%), Price T Rowe Associates Inc. MD (1.94%), Loomis Sayles & Co. L P (1.74%), Massachusetts Financial Services Co. MA (1.69%) and Clearbridge Investments LLC (1.65%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $299.23.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $76.74 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.37 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.